MedTrace Logo

Alcohol Related Impairment and Reinforcement: Pre to Post Roux en Y Gastric Bypass Surgery

NCT02370732 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-09-28

No results posted yet for this study

Summary

The proposed project will help to understand the changes in reinforcement and impairment experienced by Roux en Y bariatric surgery (RYGB) patients who consume alcohol. In this study the investigators propose to investigate RYGB patients with a prospective, longitudinal design. Investigators will examine driving impairment before and after surgery as well as study cognitive changes and reinforcement changes that may occur in RYGB patients while consuming alcohol. Finally, investigators aim to better characterize the changes that occur in the pharmacokinetics of alcohol following bariatric surgery and examine key variables which may play a role in the development in alcohol use disorders.

Conditions

  • Bariatric Surgery Candidate

Interventions

OTHER

Alcohol

A weight based dose of alcohol will be administered during each study day.

Sponsors & Collaborators

  • University of Kentucky

    collaborator OTHER

  • Kent State University

    collaborator OTHER

  • North Dakota State University

    collaborator OTHER

  • Neuropsychiatric Research Institute, Fargo, North Dakota

    lead OTHER

Principal Investigators

  • Kristine Steffen, PharmD, PhD · Neuropsychiatric Research Institute

  • Scott Engel, PhD · Neuropsychiatric Research Institute

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2018-11-30
Completion
2019-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02370732 on ClinicalTrials.gov